Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Jul;20(1):21–24. doi: 10.1128/aac.20.1.21

Pharmacology, Safety, and efficacy of cefamandole in childhood infections.

M C Thirumoorthi, A S Dajani, C V Vincent, M J Maurer
PMCID: PMC181625  PMID: 7283413

Abstract

We used cefamandole in the initial treatment of 34 children (10 months to 15 years of age) with suspected bone, joint, or soft tissue infections. The minimal inhibitory concentration of organisms encountered ranged between 0.015 and 2 microgram/ml. At 1 h after intravenous infusion of 25 mg/kg, the mean serum level of cefamandole was 26.2 microgram/ml (range, 8.9 to 47.5 microgram/ml), and at 3 h the level was 1.8 microgram/ml (range, 0.6 to 4.4 microgram/ml), which is above the minimal inhibitory concentration for most of the organisms encountered. However, when the drug was given intravenously every 6 h, the mean level after a 37-mg/kg dose was 0.9 microgram/ml (range, less than 0.5 to 1.9 microgram/ml) at 4 h and, by extrapolation, would have fallen below 0.1 microgram/ml at 6 h. The mean serum half-life was 34 min. Cefamandole appeared to diffuse well into synovial fluid, with joint fluid levels between 5 and 40 microgram/ml. The drug was tolerated well. Cefamandole appears to be a reasonable alternative in the initial treatment of skeletal infections in children, but need to be administered every 4 h to maintain suprainhibitory serum levels between doses.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agbayani M. M., Khan A. J., Kemawikasit P., Rosenfeld W., Salazar D., Kumar K., Glass L., Evans H. E. Pharmacokinetics and safety of cefamandole in newborn infants. Antimicrob Agents Chemother. 1979 May;15(5):674–676. doi: 10.1128/aac.15.5.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azimi P. A. Clinical and laboratory investigation of cefamandole in infections of infants and children. Antimicrob Agents Chemother. 1978 Jun;13(6):955–957. doi: 10.1128/aac.13.6.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang C. T., Khan A. J., Agbayani M. M., Jhaveri R., Amin I., Evans H. E. Pharmacokinetics and safety of cefamandole in infants and children. Antimicrob Agents Chemother. 1978 Dec;14(6):838–841. doi: 10.1128/aac.14.6.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Delgado D. G., Brau C. J., Cobbs C. G., Dismukes W. E. Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus spp. Bronchopulmonary infections. Antimicrob Agents Chemother. 1979 Jun;15(6):807–812. doi: 10.1128/aac.15.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eykyn S., Jenkins C., King A., Phillips I. Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin. Antimicrob Agents Chemother. 1973 Jun;3(6):657–661. doi: 10.1128/aac.3.6.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feigin R. D., Pickering L. K., Anderson D., Keeney R. E., Shackleford P. G. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics. 1975 Feb;55(2):213–223. [PubMed] [Google Scholar]
  7. Fu K. P., Neu H. C. A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides. J Infect Dis. 1978 May;137 (Suppl):S38–S50. doi: 10.1093/infdis/137.supplement.s38. [DOI] [PubMed] [Google Scholar]
  8. Greenberg R. N., Scalcini M. C., Sanders C. V., Lewis A. C. Cefamandole therapy in anaerobic infections. Antimicrob Agents Chemother. 1979 Mar;15(3):337–341. doi: 10.1128/aac.15.3.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoyme U., Madsen P. O. Cefamandole and cefazolin in the therapy of complicated urinary tract infections. J Infect Dis. 1978 May;137 (Suppl):S100–S102. doi: 10.1093/infdis/137.supplement.s100. [DOI] [PubMed] [Google Scholar]
  10. Kolyvas E., Ahronheim G., Marks M. I., Gledhill R., Owen H., Rosenthall L. Oral antibiotic therapy of skeletal infections in children. Pediatrics. 1980 May;65(5):867–871. [PubMed] [Google Scholar]
  11. Levine L. R., McCain E. Clinical experience with cefamandole for treatment of serious bone and joint infections. J Infect Dis. 1978 May;137 (Suppl):S119–S124. doi: 10.1093/infdis/137.supplement.s119. [DOI] [PubMed] [Google Scholar]
  12. Meyers B. R., Hirschman S. Z. Antibacterial activity of cefamandole in vitro. J Infect Dis. 1978 May;137 (Suppl):S25–S31. doi: 10.1093/infdis/137.supplement.s25. [DOI] [PubMed] [Google Scholar]
  13. Neu H. C. Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis. 1978 May;137 (Suppl):S80–S87. doi: 10.1093/infdis/137.supplement.s80. [DOI] [PubMed] [Google Scholar]
  14. Perkins R. L., Fass R. J., Warner J. F., Prior R. B., File T. M., Tight R. R., Gardner W. G., Ruiz D. E., Slama T. G. Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients. J Infect Dis. 1978 May;137 (Suppl):S110–S118. doi: 10.1093/infdis/137.supplement.s110. [DOI] [PubMed] [Google Scholar]
  15. Petty B. G., Smith C. R., Wade J. C., Conrad G. L., Lipsky J. J., Ellner J. J., Lietman P. S. Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia. Antimicrob Agents Chemother. 1978 Jul;14(1):13–18. doi: 10.1128/aac.14.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Prober C. G., Yeager A. S. Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis. J Pediatr. 1979 Jul;95(1):131–135. doi: 10.1016/s0022-3476(79)80106-7. [DOI] [PubMed] [Google Scholar]
  17. Rodriguez W. J., Ross S., Khan W. N., Goldenberg R. Clinical and laboratory evaluation of cefamandole in infants and children. J Infect Dis. 1978 May;137 (Suppl):S150–S154. doi: 10.1093/infdis/137.supplement.s150. [DOI] [PubMed] [Google Scholar]
  18. Simon H. J., Yin E. J. Microbioassay of antimicrobial agents. Appl Microbiol. 1970 Apr;19(4):573–579. doi: 10.1128/am.19.4.573-579.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stone H. H., Guest B. S., Geheber C. E., Kolb L. D. Cefamandole in treatment of peritonitis. J Infect Dis. 1978 May;137 (Suppl):S103–S109. doi: 10.1093/infdis/137.supplement.s103. [DOI] [PubMed] [Google Scholar]
  20. Tetzlaff T. R., McCracken G. H., Jr, Nelson J. D. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr. 1978 Mar;92(3):485–490. doi: 10.1016/s0022-3476(78)80455-7. [DOI] [PubMed] [Google Scholar]
  21. Walker S. H., Gahol V. P. Pharmacokinetics of cefamandole in infants and children. Antimicrob Agents Chemother. 1978 Sep;14(3):315–317. doi: 10.1128/aac.14.3.315. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES